Vetoquinol SA (VETO.PA)
78 €
+1.20 (+1.56%)
Rating:
Recommendation:
-
| Symbol | VETO.PA |
|---|---|
| Price | 78 € |
| Beta | 0.800 |
| Volume Avg. | 0.00M |
| Market Cap | 1.055B |
| Shares () | - |
| 52 Week Range | 76.3-98.6 |
| 1y Target Est | - |
| DCF Unlevered | VETO.PA DCF -> | |
|---|---|---|
| DCF Levered | VETO.PA LDCF -> | |
| ROE | 10.37% | Buy |
| ROA | 7.36% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 3.60% | Neutral |
| P/E | 15.69 | Strong Buy |
| P/B | 1.90 | Strong Buy |
About
Download (Excel)Mr. Matthieu Frechin
Healthcare
Drug Manufacturers—Specialty & Generic
Paris
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.